U.S. Patent No. 12,734,179 B2, titled Progesterone formulation to trigger ovulation and provide luteal phase support, was ...
CHO expression and rapid characterization help close the gap between computational design and experimental validation · ...
October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to ...
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in ...
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have ...
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted ...
Objective response rate of 45.5% and disease control rate of 72.7% observed in 11 heavily pretreated patients with recurrent ...
(Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study ...
Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and continued pipeline expansion Financing follows Incyte’s July 2026 ...
MESA, AZ / ACCESS Newswire / October 23, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that it is ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results